Reglan
Do you want an attorney on your side who has been recognized as one of Dallas/Fort Worth's best lawyers? Rachel Montes will ensure that you will not stand alone in your legal battle. The best legal counsel and affordable help is just one phone call away.
"We have a well-earned reputation for building strong cases and taking them all the way through jury trial when necessary."
Rachel Montes
TARDIVE DYSKINESIA LINKED TO REGLAN USE
Long term or high dosage use of Reglan (also known as metoclopramide), has been linked to a movement disorder called tardive dyskinesia, which can continue to affect Reglan users even after the drug is discontinued.
In February of 2009, the U.S. Food & Drug Administration (FDA) ordered the maker of Reglan to add a boxed warning about this risk to its label. In lawsuits filed against Wyeth, the manufacturer of Reglan, allegations have been made that Wyeth knew of a widespread tendency among physicians to mis-prescribe Reglan for long periods of time even though the medication is only approved for 12 months of use. REGLAN IS ONLY APPROVED FOR SHORT TERM USE OF PERIODS BETWEEN 4-12 WEEKS.
Click here to read the FDA Warning.
REGLAN is supposed to be prescribed as a short-term treatment for heartburn caused by gastroesophageal reflux in people who have used other medications without relief of symptoms. REGLAN is also used to treat slow gastric emptying in people with diabetes (also called diabetic gastroparesis), which can cause nausea, vomiting, heartburn, loss of appetite, and a feeling of fullness after meals.
In one study, the FDA found that about 20 percent of patients who used REGLAN, used it for longer than three months, longer than the 12 week period alloted for use of the product. The FDA also claims there were reports of TARDIVE DYSKINESIA in patients who used REGLAN (metoclopramide), and that the majority of those who reported these problems had taken the drug for more than three months.
WHAT IS TARDIVE DYSKINESIA?
Tardive Dyskinesia is horribly disabling condition that is characterized by repetitive, involuntary movements much like Parkinson's, but often times much more pronounced than Parkinsons. Even after the patient stops taking the medication, the side effects not only continue, but in many cases the symptoms actually worsened after the patient discontinued the use of REGLAN. To make matters worse, there is no treatment an no cure for TARDIVE DYSKINESIA.
- Were you or a loved one prescribed Reglan® or Metoclopramide?
- Have you or loved one been diagnosed with Tardive Dyskinesia?
- How long did you or your loved one take Reglan® or Metoclopramide?
- Did you or loved one experience any of the following symptoms?
- Involuntary/ repetitive movements of the extremities
- Facial tics
- Lip smacking, pursing and puckering
- Face Grimacing
- Tongue protrusion
- Rapid eye movements or blinking
- Impaired movement of the fingers.
- Restless Leg Syndrome (RLS)
A LOOK BACK AT FDA ACTIONS CONCERNING AVANDIA | Dallas, Texas Personal Injury Attorney Blog
2007 NEW ENGLAND JOURNAL OF MEDICINE ARTICLE After a 2007 study published in the New England Journal of Medicine showed a link between Avandia and an increased risk in heart attacks, on May 21, 2007, the Food and Drug Administration (FDA) issued a safety alert on May 21, 2007. However, the FDA did not ban…
SEPTEMBER 23, 2010: FDA REPORT RESTRICTING ACCESS TO AVANDIA | Dallas, Texas Personal Injury Attorney Blog
Attached is a copy of the Memorandum written by Janet Woodcock, M.D., the current Director for the Center for Drug Evaluation and Research at the FDA, FDA concerning Avandai (rosiglitazone) in which the FDA finds: the drug manufacturer had not met the FDA’s guidelines for 95% confidence for the risk ratio (test drug versus comparators)…
2007 NEW ENGLAND JOURNAL OF MEDICINE ARTICLE | Dallas, Texas Personal Injury Attorney Blog
Click on the link below to view a copy of the 2007 study published in the New England Journal of Medicine which showed a link between Avandia and an increased risk in heart attacks. The study was conducted by two doctors at the Cleveland Clinic who evaluated 42 studies that compared patients taking…